Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans.
about
OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamiliesPolymorphism of ORM1 is associated with the pharmacokinetics of telmisartanMembrane transporters in drug developmentKinetic Interpretation of the Importance of OATP1B3 and MRP2 in Docetaxel-Induced Hematopoietic Toxicity.Interaction of three regiospecific amino acid residues is required for OATP1B1 gain of OATP1B3 substrate specificity.Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity.Impact of OATP transporters on pharmacokinetics.Molecular mechanisms governing different pharmacokinetics of ginsenosides and potential for ginsenoside-perpetrated herb-drug interactions on OATP1B3.Potential role of organic anion transporting polypeptide 1B1 (OATP1B1) in the selective hepatic uptake of hematoporphyrin monomethyl ether isomers.Creatine kinase elevation caused by a combination of fluvastatin and telmisartan in a patient heterozygous for the CYP2C9*3 and ABCC2 -24C > T variants: a case report.Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.Retracted: Physiologically based pharmacokinetic predictions of intestinal BCRP-mediated effect of telmisartan on the pharmacokinetics of rosuvastatin in humans.Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.Organic anion transporting polypeptides expressed in pancreatic cancer may serve as potential diagnostic markers and therapeutic targets for early stage adenocarcinomasRole of OATP transporters in the disposition of drugs.Interaction of macrolide antibiotics with intestinally expressed human and rat organic anion-transporting polypeptides.Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects.Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters.Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties.The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance.Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption.Primary hepatocyte cultures as prominent in vitro tools to study hepatic drug transporters.Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism.Suitability of digoxin as a P-glycoprotein probe: implications of other transporters on sensitivity and specificity.In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery.Imaging transporters: Transforming diagnostic and therapeutic development.Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites.Trafficking and other regulatory mechanisms for organic anion transporting polypeptides and organic anion transporters that modulate cellular drug and xenobiotic influx and that are dysregulated in disease.Evaluation of the Interplay between Uptake Transport and CYP3A4 Induction in Micropatterned Cocultured Hepatocytes.Transporter-mediated drug--drug interactions involving OATP substrates: predictions based on in vitro inhibition studies.Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytesEstablishment of in vitro-in vivo equivalence of highly variable drugs - a generic product development perspective.No effect of MDR1 C3435T polymorphism on oral pharmacokinetics of telmisartan in 19 healthy Chinese male subjects.Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics.Combined effect of telmisartan and fluvastatin on arachidonic acid metabolism in human liver microsomes.To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics.Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition.Dynamic analysis of GI absorption and hepatic distribution processes of telmisartan in rats using positron emission tomography.First automatic radiosynthesis of 11C labeled Telmisartan using a multipurpose synthesizer for clinical research use.Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions.
P2860
Q27001267-91FDF5E5-C543-4F2B-8FA8-C8795A94ED8EQ28535089-4CA1640F-48EF-4A60-B684-1B966E49A5B7Q29616802-BB307166-03FB-4190-B87E-943C5E8241D1Q33994563-03CD3237-18D3-47E6-A93F-C7076DF46ABDQ34165400-48DDBFD0-AFE6-4955-903E-B4F7A084D95EQ34603829-E8C0EE0A-8E7F-45E2-9EE5-868C7BF6523EQ34612244-32FF6AED-7A02-4F9C-9C7C-1B4641DCC3B1Q35039217-AA0C28D6-4785-4B0E-BF5A-10FC7FBEA146Q35080119-524787CD-25A3-4B8D-B1AD-8D11C53A54FAQ35300044-CFA5FE83-1DCC-466A-BEFD-C3B351EC6857Q35846898-9DC7C6A2-F3A8-4118-9677-F56435CEDCA5Q36233941-857FAA94-6CBA-4659-AA2E-D98481759D95Q36776621-3876DC0C-1068-4359-998D-1AE9411B8234Q36800228-5E6177DF-C585-4B02-A4B5-220EDA1CD8D3Q37074085-9046ECF6-0123-44EE-812C-469D3D19ABECQ37444375-2968A6E4-E7B6-4389-AEEE-C036DE75C7D9Q37680968-C5D4FD34-ECB1-44D1-90B7-33DDF9AFE171Q37696476-33A2D664-C568-4B33-A00F-0CF75A55B5B0Q37761376-70170DBC-C1DE-41AC-B0DC-44F515474AD8Q37955160-AE71F91C-AE26-404D-9F88-15527FF802E4Q38056878-16D65359-F7A7-44A5-AF40-011F6F3B75C5Q38077993-565E67BC-8385-479E-89BD-62C94CB19CCFQ38084901-C6119B69-6D24-47B3-88C9-33374745879FQ38156114-3CFB3DF7-B51A-4A03-923B-734450102036Q38214334-672E5B51-0223-439B-BDCD-C52EC74FEDA2Q38871905-2F210A86-BF11-4C24-B30E-F6F6F0E910CEQ38888365-61253EC7-DCE9-4190-97F0-8A2C950CB653Q39181492-C35DA8BC-EA68-4875-9C13-3A9AAEDCA379Q39365193-E3C5C33D-C0B5-4E2C-93FF-5705AA744241Q39624755-6AD7F0B1-77C8-4A89-B163-D1C672A49D38Q42282480-71FE74C4-BBDF-4033-904B-C19BD117F0EAQ44912878-161EC2DD-40EF-4487-A5C2-FBA5040D0EDCQ46204090-08EE32F6-2B73-463F-8F95-304B1C874C2FQ47277562-8A17294D-2C7E-48AB-8BBD-0EC9653AC7A7Q49967937-C35BC99F-D712-42BD-8089-8563B94B2FADQ50871327-4FDE4C77-3E7E-4695-8205-6E26DB7F68F9Q51102882-0AC3D502-2E61-4C11-B584-B85A87E7517DQ53160430-8CB4F477-E9AD-4AD0-A7B1-FBA913EBDECEQ53247636-0166689A-3989-429E-9C08-99FBA42E6340Q55046512-A10FECBB-B62E-4311-8C77-EC9910DE1115
P2860
Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Predominant contribution of OA ...... eceptor antagonist, in humans.
@en
type
label
Predominant contribution of OA ...... eceptor antagonist, in humans.
@en
prefLabel
Predominant contribution of OA ...... eceptor antagonist, in humans.
@en
P2093
P356
P1476
Predominant contribution of OA ...... eceptor antagonist, in humans.
@en
P2093
Akiko Harada
Asami Saito
Kazuya Maeda
Naoki Ishiguro
Takashi Igarashi
Thomas Ebner
Wataru Kishimoto
Willy Roth
Yuichi Sugiyama
P304
P356
10.1124/DMD.105.009175
P577
2006-04-12T00:00:00Z